Efficacy and safety of anti-D for treatment of adults with immune thrombocytopenia.
This study was planned to assess the response of anti-D in patients with immune thrombocytopenia (ITP). Twenty adults (8 males: 12 females) with a median age 33.5 years (19-59 years) were included. Nine patients had newly-diagnosed ITP, 6 had persistent ITP and 5 had chronic ITP. The overall response rate was 65%. Patients with newly diagnosed ITP showed response rates of 77% (7/9), persistent ITP had response rates 50% (3/6) and patients with chronic ITP had response rates of 60% (3/5). The median time to response was 3 days (1-11 days). There was no correlation of response with age, sex, severity of bleeding, presenting platelet counts, ABO blood group or prior steroid or IVIG response.
Naithani
Rahul
R
Department of Hematology, All India Institute of Medical Science, New Delhi, India. dr_rahul6@hotmail.com
Kumar
Rajat
R
Mahapatra
M
M
Tyagi
Seema
S
Saxena
Renu
R
D000328:Adult; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000097:blood / Q000188:drug therapy*; D018029:Rho(D) Immune Globulin / Q000008:administration & dosage*; D055815:Young Adult
D018029:Rho(D) Immune Globulin